Hyderabad-based Natco Pharma Limited on Tuesday completed the acquisition of an additional 13.25 per cent equity stake in South African pharmaceutical company Adcock Ingram Holdings Proprietary Limited, bringing its total shareholding to 49 per cent.
The transaction was valued at approximately ZAR 1.81 billion, equivalent to around ₹1,060 crore at the prevailing exchange rate. The acquisition was executed through Natco Pharma South Africa Proprietary Limited, the company’s wholly owned subsidiary in the country.
This is the second leg of Natco’s entry into Adcock Ingram. The company first acquired a 35.75 per cent stake through participation in Adcock Ingram’s delisting process in 2025, which involved a firm intention offer announced in July 2025, shareholder approval in October 2025, and transaction completion in November 2025.
Adcock Ingram, established in 1891, is ranked second in South Africa’s private and public pharmaceutical market. The company holds a 10 per cent share of the private market, leads the over-the-counter pharmaceutical segment, and is the largest supplier of hospital and critical care products in the country. Its portfolio includes brands such as Panado, Allergex, and Myprodol.
Natco Pharma’s stock on the NSE was trading at ₹967.70 on Tuesday afternoon, down 1.25 per cent from the previous close of ₹979.95. The company carries a total market capitalisation of approximately ₹17,332 crore and is listed on the Nifty Smallcap 100 index.